Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves boceprevir, the first protease inhibitor for hepatitis C, without overly proscriptive labeling.
You may also be interested in...
Merck Makes Hepatitis C A Priority
Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.
Vertex Out To Significant Early Lead In HCV Protease Inhibitor Competition With Merck
Most market analysts predicted Vertex's protease inhibitor would be a bigger seller than Merck's, but a greater than 10-to-1 disparity in third-quarter net sales is still eye-opening.